| 1.7584 0.058 (3.44%) | 09-11 13:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.02 | 1-year : | 2.36 |
| Resists | First : | 1.73 | Second : | 2.02 |
| Pivot price | 1.64  |
|||
| Supports | First : | 1.49 |
Second : | 1.35 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.62 |
| MA(100) : | 1.28 |
MA(250) : | 1.74 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.7 |
D(3) : | 84.3 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 2.68 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALZN ] has closed above bottom band by 43.9%. Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.7 - 1.71 | 1.71 - 1.72 |
| Low: | 1.55 - 1.57 | 1.57 - 1.58 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Thu, 10 Sep 2026
Alzamend Neuro Q1 Results: EPS misses estimate, losses widen - scanx.trade
Thu, 10 Sep 2026
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary - TradingView
Thu, 10 Sep 2026
ALZN: Net loss rose to $3.0 million as cash increased to $7.6 million, but funding risks persist - TradingView
Thu, 10 Sep 2026
Alzamend Neuro (ALZN) raises cash but says conditions raise doubt it can keep operating - stocktitan.net
Tue, 08 Sep 2026
ALZN Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Thu, 20 Aug 2026
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 56.7 (%) |
| Shares Short | 177 (K) |
| Shares Short P.Month | 328 (K) |
| EPS | -2.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -164 % |
| Return on Equity (ttm) | -373.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 9.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|